- Home
- KOD vs LU Comparison
KOD vs LU Comparison
Compare KOD & LU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | LU |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KOD | LU |
|---|---|---|
| Price | $45.52 | $1.89 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 1 |
| Target Price | ★ $35.43 | $2.00 |
| AVG Volume (30 Days) | ★ 1.1M | 943.4K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.33 | $1.73 |
| 52 Week High | $47.84 | $4.57 |
Technical Indicators
Market Signals| Indicator | KOD | LU |
|---|---|---|
| Relative Strength Index (RSI) | 63.05 | 42.54 |
| Support Level | $21.82 | $1.73 |
| Resistance Level | $45.60 | $2.77 |
| Average True Range (ATR) | 3.11 | 0.08 |
| MACD | -0.39 | 0.02 |
| Stochastic Oscillator | 71.41 | 15.52 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.